JD, MS, MBA
CEO / President / Founder
David has been our CEO since our founding in 2007. He has been leading our manufacturing process development, now in increasing scale GMP manufacturing. In his PhD studies in Pharmaceutical Chemistry at the University of California San Francisco he helped invent a successful drug delivery system (PEG liposomes, used in Doxil and other products). Earlier, he was first to synthesize Iotrolan, a commercially important contrast agent still in use 35 years later.
He is an experienced business executive with 19 years experience as VP or CEO. For 3 years he was VP and primary attorney of FormFactor, a startup company that has been successfully public sine 2003. In 2001, he took Verisity Ltd. public as its General Counsel and remained in that role until the company was acquired in 2005.
Chief Medical Officer
Dr. John Galgiani is widely recognized as one of the leading experts on Valley Fever. Since his fellowship with David A Stevens at Stanford University and joining the University of Arizona College of Medicine in 1978, Dr. Galgiani has focused on this disease.
He is the author of over 250 scientific papers and book chapters, most of which focus on medical mycology in general and Valley Fever in particular. For over twenty-five years, Dr. Galgiani was the Subproject Director for Valley Fever clinical trials conducted by the NIH-supported Mycoses Study Group. During this time, he led the largest multicenter trial of fluconazole treatment for Valley Fever meningitis, led the only randomized double-blinded trial of any two antifungal treatments for Valley Fever, and collaborated with others on multiple phase II trials of a variety of azole treatments for Valley Fever.
He founded and has directed the Valley Fever Center for Excellence at the University of Arizona College of Medicine since 1996. This now includes a clinical center in Phoenix focusing exclusively on Valley Fever. In addition to Dr. Galgiani’s own research interests into treatments, improved diagnostics, and vaccines for Valley Fever, the Valley Fever Center has encouraged the research of others and helped to connect clinicians across Arizona in the care of their patients. This provides a valuable platform for assessing new therapies such as nikkomycin Z.